Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Intestinal failure associated liver disease is a cholestatic liver disease associated with
prolonged need for parenteral nutrition that can lead to such significant complications as
liver failure. In the neonatal population, infants with history of intestinal resection and
short bowel syndrome are at increased risk for this disease. The investigators plan to
compare two possible lipid dosing preventative strategies including a composite, fish oil
lipid and soy-based lipid reduction.